Skip to main content
Supplement ScienceSupplementScience
review1,258 participants

Alpha-Lipoic Acid for Neuropathy: Route and Trial Duration

·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

A 2004 meta-analysis of four trials and 1,258 patients found that intravenous ALA 600 mg/day for three weeks improved...

A 2004 meta-analysis of four trials and 1,258 patients found that intravenous ALA 600 mg/day for three weeks improved neuropathy symptoms. Oral SYDNEY 2 studied 181 patients for five weeks and favored 600 mg/day over placebo. NATHAN 1 did not improve its primary four-year composite endpoint, so short-term symptom benefit should not be restated as proven nerve regeneration.

Key Findings

  • The 2004 meta-analysis evaluated intravenous 600 mg/day for three weeks, not 15 oral trials. TSS responder rates were 52.7% with ALA and 36.9% with placebo.
  • SYDNEY 2 randomized 181 patients to oral 600, 1,200 or 1,800 mg/day or placebo for five weeks. Mean TSS decreased 4.9 points at 600 mg versus 2.9 points with placebo.
  • Higher oral doses did not provide a clear added symptom benefit and caused more nausea, vomiting and vertigo.
  • NATHAN 1 randomized 460 patients to oral 600 mg/day or placebo for four years. The primary composite endpoint did not differ significantly (p=0.105), though some secondary impairment measures improved.
  • NATHAN 1 reported more serious adverse events in the ALA group (38.1%) than placebo (28.0%). Neither study establishes a dose-equivalence conversion between isolated R-ALA and racemic ALA.

Study Details

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis
Ziegler D, Nowak H, Kempler P, Vargha P, Low PA — Diabet Med (2004)
Four intravenous trials of 600 mg/day over three weeks showed improved symptom scores versus placebo.
1,258 participantsModerate
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. — Diabetes Care (2006)
Five-week oral trial:600 mg/day improved TSS by 4.9 points from baseline versus 2.9 with placebo; higher doses increased adverse effects.
181 participantsModerate
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial
Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. — Diabetes Care (2011)
Four-year trial: primary composite endpoint not significant; some secondary impairment endpoints improved and serious adverse events were more frequent with ALA.
460 participantsModerate

Practical Takeaway

Separate intravenous treatment, short-term oral symptom relief and long-term neuropathy outcomes. The cited oral trial used 600 mg/day; it does not support a 600 mg R-ALA versus 1,200 mg racemic conversion. Discuss potential benefit, glucose effects and adverse events with the diabetes-care clinician while maintaining established neuropathy care.

Summary

A four-trial intravenous meta-analysis, the five-week oral SYDNEY 2 trial and the four-year NATHAN 1 trial assessed different alpha-lipoic-acid outcomes in diabetic neuropathy.

Related Supplements

Alpha-Lipoic Acid

Related Conditions

Longevity & Healthy AgingBlood Sugar ManagementNeuropathy

Learn More

Methylene Blue Benefits: Brain Energy, Nootropic Claims, and Major Safety Warnings

Frequently Asked Questions

Does ALA help diabetic neuropathy symptoms?

Short intravenous trials and the five-week oral SYDNEY 2 trial found symptom improvements. This is different from proving nerve regeneration or long-term prevention of neuropathy progression.

What oral dose did SYDNEY 2 study?

It compared 600, 1,200 and1,800 mg/day with placebo. The authors judged 600 mg/day to have the best benefit-risk balance in that five-week trial; higher doses caused more adverse effects.

Can I convert the trial dose to a smaller R-ALA dose?

These trials do not establish an equivalent dose of isolated R-ALA. Do not use a claimed two-to-one bioavailability conversion as a proven treatment-equivalence rule.

Did the four-year trial prove prevention of progression?

Its primary composite endpoint did not differ significantly between groups. Some secondary impairment measures favored ALA, but that finding should not be presented as established overall disease prevention.

Are intravenous and oral results interchangeable?

No. The intravenous meta-analysis lasted three weeks; SYDNEY 2 tested oral dosing for five weeks. Route, duration and measured outcomes must remain attached to the correct study.

Continue Reading

Supplement Guide

Alpha-Lipoic Acid

Bottom line: ALA is a uniquely versatile antioxidant with strong evidence for nerve pain and blood sugar. Take 300-600mg R-lipoic acid daily for broad cellular protection.

Condition Guide

Longevity & Healthy Aging

References

  1. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine. DOI PubMed
  2. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R (2006). Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. DOI PubMed
  3. Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ (2011). Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. DOI PubMed